$CDLX

CDLX (NASDAQ: CDLX) files Form 144 for 40,296-share resale tied to vesting

Cardlytics, Inc. (NASDAQ: CDLX) has filed Form 144, indicating a proposed resale of 40,296 shares of Common Stock. This resale is linked to Restricted Stock Vesting that occurred on March 31, 2026. The filing also notes a previous sale of 6,253 shares by Nicholas H. Lynton on January 5, 2026.

Original reporting
Published Apr 1, 2026, 7:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 1, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CDLX
Neutral
medium confidence
Mentioned
$CDLX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$CDLXNeutralMed
01

Why it matters

The insider resale may temporarily increase stock supply, potentially leading to a short-term price decline. Market perception will depend on broader investor sentiment and overall trading volume.

02

Market read

While the insider sale is noteworthy, it is a routine event and unlikely to cause significant long-term impact unless accompanied by other negative signals.

03

What to watch

Market conditions, overall sector performance, and upcoming company fundamentals or earnings reports could mitigate or amplify the impact of insider activity.

Timing: Immediate (within days)

Background

Cardlytics filed Form 144 indicating the sale of 40,296 shares, linked to vesting events that occurred on March 31, 2026. This follows a previous sale of 6,253 shares by Nicholas H. Lynton on January 5, 2026.

Company-level read

Ticker impact

$CDLXNeutralMedium confidence
Context

The filing indicates insider activity related to stock vesting and potential resale, which can influence stock supply and investor perception.

Expected impact

Moderate short-term decline of approximately 2-4%, depending on market conditions.

Evidence & confidence

Insider sales tied to vesting are common and do not necessarily indicate negative outlooks; however, increased supply can influence price dynamics, especially if accompanied by low trading volume.

Market effects

Potential short-term pressure on the technology and financial services sectors if multiple insider sales occur.

Limited; primarily affects the NASDAQ and related regional indices.

Negligible; the event is company-specific and does not impact global markets.

Counterpoint

Insider sales tied to vesting may be routine and not indicative of negative sentiment; the stock could remain stable or rebound after initial sell-off.

Key entities

  • Cardlytics, Inc.

    A marketing technology company that provides purchase intelligence and marketing automation solutions.

  • Nicholas H. Lynton

    A director or executive of Cardlytics involved in the previous sale.

Related articles

$CDLXMedAI 8/10

Cardlytics (CDLX) Q2 2026 Earnings Call Transcript

Cardlytics (CDLX) reported Q2 2026 results on an earnings call. Revenue was $36.9M, down 36% YoY, with billings $65.5M (-34%) and adjusted contribution $21.3M (-32%). Net loss was $14.9M. Q3 2026 guidance: billings $61M-$67M, revenue $34M-$39M, adjusted EBITDA $0M-$3M. Cash was $28M.

$CDLXMedAI 8/10

Cardlytics: Q2 Earnings Snapshot

Cardlytics (CDLX) reported a Q2 loss of $14.9 million, or $2.58 per share. Adjusted for discontinued operations, the loss was $1.50 per share. Revenue was $36.9 million. For the quarter ending September, the company expects revenue of $34 million to $39 million.

$CDLXMed

Cardlytics, Inc. (CDLX): Results of Operations and Financial Condition

Cardlytics, Inc. (CDLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance • Company delivers strong second quarter results: ◦ Revenues of $36.9 million ◦ Billings of $65.5 million ◦ Adjusted Contribution of $21.3 million ◦ Net Loss of $(14.9) million

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.